BTIG Research Boosts CeriBell (NASDAQ:CBLL) Price Target to $30.00

CeriBell (NASDAQ:CBLL) had its price target hoisted by equities research analysts at BTIG Research from $28.00 to $30.00 in a note issued to investors on Tuesday, MarketBeat.com reports. The brokerage presently has a “buy” rating on the stock. BTIG Research’s target price would indicate a potential upside of 22.95% from the stock’s previous close.

Other analysts have also recently issued research reports about the company. Weiss Ratings upgraded CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday. Canaccord Genuity Group lifted their target price on CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $22.40.

CeriBell Trading Up 4.6%

CBLL opened at $24.40 on Tuesday. CeriBell has a 12-month low of $10.85 and a 12-month high of $24.44. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.18 and a quick ratio of 8.79. The stock has a market capitalization of $936.47 million, a PE ratio of -13.86 and a beta of 0.81. The firm’s fifty day moving average price is $19.06 and its 200 day moving average price is $19.10.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.04). The company had revenue of $28.10 million for the quarter, compared to the consensus estimate of $27.28 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. As a group, research analysts expect that CeriBell will post -1.96 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, major shareholder Tpg Gp A, Llc sold 202,368 shares of the business’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $20.12, for a total transaction of $4,071,644.16. Following the completion of the sale, the insider owned 3,765,054 shares of the company’s stock, valued at $75,752,886.48. This represents a 5.10% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Joseph Michael Taylor sold 13,095 shares of the stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $23.40, for a total transaction of $306,423.00. Following the sale, the director owned 48,478 shares in the company, valued at approximately $1,134,385.20. This trade represents a 21.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 313,780 shares of company stock worth $6,241,749. Corporate insiders own 17.70% of the company’s stock.

Institutional Trading of CeriBell

A number of institutional investors and hedge funds have recently made changes to their positions in CBLL. Caitong International Asset Management Co. Ltd boosted its position in CeriBell by 3,971.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after purchasing an additional 1,231 shares during the period. Strs Ohio acquired a new stake in CeriBell in the first quarter worth $27,000. CWM LLC lifted its stake in CeriBell by 1,178.5% in the fourth quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after buying an additional 1,697 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in CeriBell by 353.8% in the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after buying an additional 1,801 shares during the last quarter. Finally, Legal & General Group Plc acquired a new position in shares of CeriBell during the second quarter valued at $53,000.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.